Overall rank by patents
#44,171
of 49,997 tracked assignees
USPTO PatentsView assignee record - 6 granted patents across 6 technology areas, recorded in grant years 2022–2025. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations).
The verdict
According to USPTO PatentsView, Xuanzhu ranks #44,171 of 49,997 tracked US assignees by granted-patent volume, with 6 patents across 6 technology areas.
USPTO PatentsView assignee plate
Corpus R44171 · Foreign Corporation #44,171 · 6 grants
GRANTS-MICRO · LOWER-Q · PHOTO-FINISH · CPC-NARROW · INNOV-PAR · CLAIMS-RICH · TYPE-FRNCORP · SPAN-YRS · BOOK-RICH
Nearest grant-volume peer: Xingmai Innovation Technology (SUZHOU) Co., Ltd. (±0 grants)
Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.
Lowest and highest poles plus nearest Innovation Score peers, not a full corpus board reprint.
Qualcomm Incorporated · highest
85 score
Xuanzhu Biopharmaceu… · this assignee
43 score
3D Lighting… · lowest
7 score
What this shows Xuanzhu's Innovation Score is 42.7/100 (top 30% of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.
Xuanzhu Biopharmaceutical Co., Ltd. is a focused PatentsView assignee: 6 CPC subclasses with 100% of grants classified under A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations). Peak complete grant year is 2022 (3 grants) versus a trough of 1 in 2024. By volume, Xuanzhu sits between Xingmai Innovation Technology (SUZHOU) Co., Ltd. and XYZ Energy Group, LLC.
Xuanzhu Biopharmaceutical Co., Ltd. shows 4 grants in 2022–2024 against only 0 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.
Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀
Xingmai Innovation Technology (SUZHOU) Co., Ltd.
6 patents
Xl-protein GMBH
6 patents
Xraydepot LLC
6 patents
Xtralis Global
6 patents
Xuzhou Zhirun Mining Equipment Science AND Technology Co., Ltd
6 patents
Xvivo Perfusion AB
6 patents
Xyphos Biosciences Inc.
6 patents
XYZ Energy Group, LLC
6 patents
Xuanzhu Biopharmaceutical Co., Ltd.
6 patents
What this shows Xuanzhu holds 6 patents at rank #44,124, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.
By rank, the assignees closest to #44,124 in granted patent volume.
Other assignees with the most granted patents in Xuanzhu's primary technology class.
Xuanzhu's Innovation Score vs. every tracked assignee
Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)
43 Top 30% higher than 70% of 49,997 US assignees
Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.
Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025
Teal-shaded recent years (2020–present) versus the 2022–2019 baseline. Full figures in the table below.
| Year | Patents Granted | Share of Period |
|---|---|---|
| 2022 | 3 | 50.0% |
| 2024 | 1 | 16.7% |
| 2025partial year | 2 | 33.3% |
Top 6 of 6 technology areas
Overall rank by patents
#44,171
of 49,997 tracked assignees
42.7 out of 100
What to do with this data
Xuanzhu Biopharmaceutical Co., Ltd.'s patent record in context - here's where to go next.
Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.
Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.